Nuvation Bio Secures Label Update for Lung Cancer Therapy IBTROZI

The regulatory approval arrives four months ahead of the anticipated schedule, incorporating data from the pivotal TRUST-I and TRUST-II studies. With a median follow-up reaching 51 months, the updated label highlights a median duration of response of 49.7 months for patients who have not previously received ROS1 tyrosine kinase inhibitors. Nuvation Bio noted that these findings were achieved without any new safety signals, maintaining the established profile of the therapy.

David Hung, CEO of Nuvation Bio, described the update as a practical tool for physicians and patients navigating a new diagnosis. By codifying a response duration exceeding four years, the label provides families with a clearer expectation of therapeutic longevity. The data, recently presented at the American Association for Cancer Research Annual Meeting and published in the Journal of Clinical Oncology, solidifies the role of IBTROZI as a frontline option for advanced disease.